- Published on
Emergency And Acute Medicine – Hemophilia
Basics And Description
Hemophilia is a hereditary bleeding disorder caused by deficiency of functional clotting factor VIII or factor IX, resulting in impaired activation of the coagulation cascade and defective hemostasis. Hemophilia A is due to factor VIII deficiency, while hemophilia B (Christmas disease) is due to factor IX deficiency. Clinical severity depends on residual factor activity. Mild disease (5–30% activity) presents with bleeding after major trauma or surgery. Moderate disease (1–5% activity) causes bleeding with trauma or surgery and occasional spontaneous hemarthroses. Severe disease (<1% activity) leads to spontaneous bleeding beginning in infancy, often occurring weekly and frequently requiring factor replacement. major complications include fatal hemorrhage, progressive joint destruction from recurrent hemarthroses, transfusion-transmitted infections (now rare with purified products), development of inhibitors—igg antibodies that neutralize clotting factors.< />pan>
Etiology
Hemophilia is inherited in an X-linked recessive pattern, although approximately one-third of cases arise from spontaneous mutations. Hemophilia A occurs in approximately 1 in 5,000–7,000 males, while hemophilia B occurs in about 1 in 30,000 males. Inhibitors develop in roughly 20% of patients with severe hemophilia A and fewer than 5% of those with severe hemophilia B.
Clinical Presentation And Symptoms
Bleeding manifestations include hemarthrosis, most commonly affecting the knee, followed by elbow, ankle, shoulder, and wrist. Other presentations include muscle hemorrhage, prolonged bleeding from soft tissue lacerations, post–dental extraction or oral mucosal bleeding, epistaxis in severe disease, hematuria, gastrointestinal bleeding, intracranial hemorrhage, and pseudotumors formed by encapsulated blood collections.
Essential Workup
Evaluation begins with a thorough history and physical examination, including bleeding pattern, known factor deficiency, baseline factor levels, inhibitor status, and prior treatments.
Diagnostic Tests And Interpretation
Laboratory findings typically show a normal platelet count, normal bleeding time, normal prothrombin time, and prolonged partial thromboplastin time. Urinalysis may reveal asymptomatic hematuria. Specific factor assays demonstrate decreased factor VIII or IX activity. Von Willebrand factor levels are normal, helping distinguish hemophilia from von Willebrand disease. Imaging is guided by clinical presentation and may include CT of the head for suspected intracranial hemorrhage, renal ultrasound or cystoscopy for persistent hematuria, or abdominal CT for suspected retroperitoneal bleeding.
Differential Diagnosis
Consider von Willebrand disease, anticoagulant or antiplatelet medication use, thrombocytopenia, and hepatic dysfunction.
Initial Stabilization And Therapy
Bleeding control begins immediately with proximal pressure when appropriate. Establish IV access and obtain type and screen. Packed red blood cells may be required for significant blood loss. Early factor replacement is critical and should not be delayed for imaging or consultation.
Emergency Department Management
Patients often know their diagnosis, factor type, dose, and inhibitor status. Emergency care should be coordinated with the patient’s hematologist whenever possible. Factor replacement should be initiated immediately for any suspected bleed.
Desired factor activity depends on bleeding severity. For low to moderate bleeding, target 30–50% activity. For moderate to severe bleeding, including gastrointestinal or genitourinary hemorrhage, target 50–100%. For life-threatening bleeding such as intracranial hemorrhage, major trauma, or airway compromise, target 100% activity.
Factor VIII dosing is calculated as body weight (kg) × 0.5 × desired percent activity, with dosing every 12 hours. Factor IX dosing is calculated as body weight (kg) × desired percent activity, with dosing every 24 hours.
Hemarthrosis is managed with splinting, compression, and ice; arthrocentesis is rarely indicated. Muscle hemorrhage requires monitoring for compartment syndrome, particularly in the forearm, calf, or iliopsoas. Oral and dental bleeding may benefit from local hemostatic agents and antifibrinolytics. Hematuria is usually mild and managed with hydration; antifibrinolytics and cryoprecipitate should be avoided. All head injuries are treated as significant, and therapy must precede imaging. Gastrointestinal bleeding requires factor replacement before endoscopic procedures.
Medications And Factor Therapy
First-line treatment for patients without inhibitors is recombinant factor VIII or IX concentrates. Plasma-derived factor concentrates are second-line options. Cryoprecipitate is reserved for hemophilia A only when factor concentrates are unavailable. Fresh frozen plasma may be used temporarily in life-threatening bleeding if specific factors are delayed.
Adjunctive therapies include desmopressin for mild hemophilia A, antifibrinolytics for mucosal bleeding, and topical thrombin for superficial wounds.
For patients with inhibitors, recombinant factor VIIa is first-line therapy, with activated prothrombin complex concentrates as second-line options. High-dose factor concentrates may be considered in low-titer inhibitor patients. Intramuscular injections and aspirin-containing products must be avoided.
Disposition And Follow-Up
There should be a low threshold for hospital admission. Indications include joint or muscle bleeds, internal hemorrhage, severe bleeding, need for repeated transfusions, complications, or any head trauma. Minor superficial bleeding with complete control may be discharged with close follow-up. All patients require hematology consultation and outpatient follow-up, with instructions to return immediately for recurrent or worsening bleeding.
Clinical Pearls And Common Errors
Never delay factor replacement while awaiting imaging in suspected serious bleeding, especially head trauma. In unknown factor levels, assume zero activity and treat as severe disease. Be familiar with management differences in patients with and without inhibitors. Replace factor before transfers, procedures, or consultations. Maintain a low threshold for admission and hematology involvement.
Basics And Description
Hemophilia is a hereditary bleeding disorder caused by deficiency of functional clotting factor VIII or factor IX, resulting in impaired activation of the coagulation cascade and defective hemostasis. Hemophilia A is due to factor VIII deficiency, while hemophilia B (Christmas disease) is due to factor IX deficiency. Clinical severity depends on residual factor activity. Mild disease (5–30% activity) presents with bleeding after major trauma or surgery. Moderate disease (1–5% activity) causes bleeding with trauma or surgery and occasional spontaneous hemarthroses. Severe disease (<1% activity) leads to spontaneous bleeding beginning in infancy, often occurring weekly and frequently requiring factor replacement. major complications include fatal hemorrhage, progressive joint destruction from recurrent hemarthroses, transfusion-transmitted infections (now rare with purified products), development of inhibitors—igg antibodies that neutralize clotting factors.< />pan>
Etiology
Hemophilia is inherited in an X-linked recessive pattern, although approximately one-third of cases arise from spontaneous mutations. Hemophilia A occurs in approximately 1 in 5,000–7,000 males, while hemophilia B occurs in about 1 in 30,000 males. Inhibitors develop in roughly 20% of patients with severe hemophilia A and fewer than 5% of those with severe hemophilia B.
Clinical Presentation And Symptoms
Bleeding manifestations include hemarthrosis, most commonly affecting the knee, followed by elbow, ankle, shoulder, and wrist. Other presentations include muscle hemorrhage, prolonged bleeding from soft tissue lacerations, post–dental extraction or oral mucosal bleeding, epistaxis in severe disease, hematuria, gastrointestinal bleeding, intracranial hemorrhage, and pseudotumors formed by encapsulated blood collections.
Essential Workup
Evaluation begins with a thorough history and physical examination, including bleeding pattern, known factor deficiency, baseline factor levels, inhibitor status, and prior treatments.
Diagnostic Tests And Interpretation
Laboratory findings typically show a normal platelet count, normal bleeding time, normal prothrombin time, and prolonged partial thromboplastin time. Urinalysis may reveal asymptomatic hematuria. Specific factor assays demonstrate decreased factor VIII or IX activity. Von Willebrand factor levels are normal, helping distinguish hemophilia from von Willebrand disease. Imaging is guided by clinical presentation and may include CT of the head for suspected intracranial hemorrhage, renal ultrasound or cystoscopy for persistent hematuria, or abdominal CT for suspected retroperitoneal bleeding.
Differential Diagnosis
Consider von Willebrand disease, anticoagulant or antiplatelet medication use, thrombocytopenia, and hepatic dysfunction.
Initial Stabilization And Therapy
Bleeding control begins immediately with proximal pressure when appropriate. Establish IV access and obtain type and screen. Packed red blood cells may be required for significant blood loss. Early factor replacement is critical and should not be delayed for imaging or consultation.
Emergency Department Management
Patients often know their diagnosis, factor type, dose, and inhibitor status. Emergency care should be coordinated with the patient’s hematologist whenever possible. Factor replacement should be initiated immediately for any suspected bleed.
Desired factor activity depends on bleeding severity. For low to moderate bleeding, target 30–50% activity. For moderate to severe bleeding, including gastrointestinal or genitourinary hemorrhage, target 50–100%. For life-threatening bleeding such as intracranial hemorrhage, major trauma, or airway compromise, target 100% activity.
Factor VIII dosing is calculated as body weight (kg) × 0.5 × desired percent activity, with dosing every 12 hours. Factor IX dosing is calculated as body weight (kg) × desired percent activity, with dosing every 24 hours.
Hemarthrosis is managed with splinting, compression, and ice; arthrocentesis is rarely indicated. Muscle hemorrhage requires monitoring for compartment syndrome, particularly in the forearm, calf, or iliopsoas. Oral and dental bleeding may benefit from local hemostatic agents and antifibrinolytics. Hematuria is usually mild and managed with hydration; antifibrinolytics and cryoprecipitate should be avoided. All head injuries are treated as significant, and therapy must precede imaging. Gastrointestinal bleeding requires factor replacement before endoscopic procedures.
Medications And Factor Therapy
First-line treatment for patients without inhibitors is recombinant factor VIII or IX concentrates. Plasma-derived factor concentrates are second-line options. Cryoprecipitate is reserved for hemophilia A only when factor concentrates are unavailable. Fresh frozen plasma may be used temporarily in life-threatening bleeding if specific factors are delayed.
Adjunctive therapies include desmopressin for mild hemophilia A, antifibrinolytics for mucosal bleeding, and topical thrombin for superficial wounds.
For patients with inhibitors, recombinant factor VIIa is first-line therapy, with activated prothrombin complex concentrates as second-line options. High-dose factor concentrates may be considered in low-titer inhibitor patients. Intramuscular injections and aspirin-containing products must be avoided.
Disposition And Follow-Up
There should be a low threshold for hospital admission. Indications include joint or muscle bleeds, internal hemorrhage, severe bleeding, need for repeated transfusions, complications, or any head trauma. Minor superficial bleeding with complete control may be discharged with close follow-up. All patients require hematology consultation and outpatient follow-up, with instructions to return immediately for recurrent or worsening bleeding.
Clinical Pearls And Common Errors
Never delay factor replacement while awaiting imaging in suspected serious bleeding, especially head trauma. In unknown factor levels, assume zero activity and treat as severe disease. Be familiar with management differences in patients with and without inhibitors. Replace factor before transfers, procedures, or consultations. Maintain a low threshold for admission and hematology involvement.
0 Comments
